Next Article in Journal
Innate Immune Response to Tick-Borne Pathogens: Cellular and Molecular Mechanisms Induced in the Hosts
Next Article in Special Issue
Antitumoral Drug: Loaded Hybrid Nanocapsules Based on Chitosan with Potential Effects in Breast Cancer Therapy
Previous Article in Journal
Genetics in Cartilage Lesions: Basic Science and Therapy Approaches
Open AccessReview

Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma

1
Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Human Anatomy, University of Palermo, 90127 Palermo, Italy
2
Department of Anatomy, School of Medicine, Tehran University of Medical Science, Tehran 141 765 3911, Iran
3
Department of Oncology and Molecular Medicine, National Institute of Health, 00161 Rome, Italy
4
Euro-Mediterranean Institute of Science and Technology (IEMEST), 90139 Palermo, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(15), 5432; https://doi.org/10.3390/ijms21155432
Received: 6 July 2020 / Revised: 24 July 2020 / Accepted: 27 July 2020 / Published: 30 July 2020
(This article belongs to the Special Issue Nanoparticles Based on Smart Polymers for Biomedical Applications)
Research for the most selective drug delivery to tumors represents a fascinating key target in science. Alongside the artificial delivery systems identified in the last decades (e.g., liposomes), a family of natural extracellular vesicles (EVs) has gained increasing focus for their potential use in delivering anticancer compounds. EVs are released by all cell types to mediate cell-to-cell communication both at the paracrine and the systemic levels, suggesting a role for them as an ideal nano-delivery system. Malignant pleural mesothelioma (MPM) stands out among currently untreatable tumors, also due to the difficulties in achieving an early diagnosis. Thus, early diagnosis and treatment of MPM are both unmet clinical needs. This review looks at indirect and direct evidence that EVs may represent both a new tool for allowing an early diagnosis of MPM and a potential new delivery system for more efficient therapeutic strategies. Since MPM is a relatively rare malignant tumor and preclinical MPM models developed to date are very few and not reliable, this review will report data obtained in other tumor types, suggesting the potential use of EVs in mesothelioma patients as well. View Full-Text
Keywords: extracellular vesicles; exosomes; drug delivery systems; malignant pleural mesothelioma extracellular vesicles; exosomes; drug delivery systems; malignant pleural mesothelioma
Show Figures

Figure 1

MDPI and ACS Style

Burgio, S.; Noori, L.; Marino Gammazza, A.; Campanella, C.; Logozzi, M.; Fais, S.; Bucchieri, F.; Cappello, F.; Caruso Bavisotto, C. Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma. Int. J. Mol. Sci. 2020, 21, 5432. https://doi.org/10.3390/ijms21155432

AMA Style

Burgio S, Noori L, Marino Gammazza A, Campanella C, Logozzi M, Fais S, Bucchieri F, Cappello F, Caruso Bavisotto C. Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma. International Journal of Molecular Sciences. 2020; 21(15):5432. https://doi.org/10.3390/ijms21155432

Chicago/Turabian Style

Burgio, Stefano; Noori, Leila; Marino Gammazza, Antonella; Campanella, Claudia; Logozzi, Mariantonia; Fais, Stefano; Bucchieri, Fabio; Cappello, Francesco; Caruso Bavisotto, Celeste. 2020. "Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma" Int. J. Mol. Sci. 21, no. 15: 5432. https://doi.org/10.3390/ijms21155432

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop